• Active cancer treatment: Monitoring tumour activity and molecular changes during chemotherapy, targeted therapy or immunotherapy.
• Baseline therapy planning: Establishing circulating tumour biomarkers prior to initiating treatment.
• Assessment of treatment response: Evaluating whether tumour burden or molecular characteristics are changing over time.
• Monitoring for cancer recurrence: Follow-up in individuals in remission or after completion of treatment.
• Therapy resistance concerns: Supporting clinical investigation where disease progression or reduced treatment effectiveness is suspected.
• Metastatic or advanced disease management: Informing ongoing therapeutic strategy in complex oncology cases.

Overview

Cancertrack™ Therapy Management analyses circulating tumour DNA (ctDNA), circulating tumour cells (CTCs) and additional tumour-associated molecular signals detectable in peripheral blood. These biomarkers can reflect tumour burden, biological behaviour and emerging genetic changes relevant to treatment planning.

Monitoring tumour-derived material in blood may provide earlier insight into disease progression, recurrence or evolving treatment resistance compared with conventional imaging or symptom-based follow-up alone. This information can help clinicians adjust therapeutic strategies in a more timely and targeted way.

Results are interpreted alongside tumour subtype, staging investigations, treatment history and overall oncological assessment. Integrating molecular monitoring with established clinical pathways may support more personalised therapy management and longer-term disease surveillance.

Practical

Specimen

Whole blood 

Container

• 2 x DCGL Streck tubes
• 2 x EDTA tubes (purple colour cap) of 10 ml each

Volume

15-20 mL

Patient preparation

Require 5-6 hours fasting prior collection